GlycoMantra, a University of Maryland, Baltimore (UMB) startup company developing therapeutics for unmet medical needs in prostate cancer, NASH liver fibrosis, and type 2 diabetes, has been granted
Log in met Medi-Access
Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen
UMB grants GlycoMantra exclusive license to advance company's therapeutic pipeline
Pharma Biz | Geplaatst op 09.03.2022 11:40